JP2001515712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001515712A5 JP2001515712A5 JP2000510770A JP2000510770A JP2001515712A5 JP 2001515712 A5 JP2001515712 A5 JP 2001515712A5 JP 2000510770 A JP2000510770 A JP 2000510770A JP 2000510770 A JP2000510770 A JP 2000510770A JP 2001515712 A5 JP2001515712 A5 JP 2001515712A5
- Authority
- JP
- Japan
- Prior art keywords
- april
- use according
- blocking agent
- suppressing
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002981 blocking agent Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003213 activating Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 APRILとそのレセプターとの間のシグナル伝達経路に関与する免疫応答を処置、抑制、活性化、または改変するための医薬品の調製のための、および癌の進行を処置、抑制、または改変するための医薬品の調製のための、該APRILとそのレセプターとの間の会合を妨げ得るブロッキング剤の使用。
【請求項2】 前記免疫応答がヒト癌細胞を含む、請求項1に記載の使用。
【請求項3】 前記ブロッキング剤が、APRILの改変型阻害形態、または抗APRIL抗体もしくは生物学的に活性なそのフラグメントである、請求項1に記載の使用。
【請求項4】 前記ブロッキング剤が、抗APRILレセプター抗体である、請求項3に記載の使用。
【請求項5】 前記ブロッキング剤が、少なくとも1つの化学療法剤と組み合わせて患者に投与される、請求項1に記載の使用。
【請求項6】 前記患者に放射線治療を施す工程をさらに包含する、請求項4に記載の使用。
【請求項1】 APRILとそのレセプターとの間のシグナル伝達経路に関与する免疫応答を処置、抑制、活性化、または改変するための医薬品の調製のための、および癌の進行を処置、抑制、または改変するための医薬品の調製のための、該APRILとそのレセプターとの間の会合を妨げ得るブロッキング剤の使用。
【請求項2】 前記免疫応答がヒト癌細胞を含む、請求項1に記載の使用。
【請求項3】 前記ブロッキング剤が、APRILの改変型阻害形態、または抗APRIL抗体もしくは生物学的に活性なそのフラグメントである、請求項1に記載の使用。
【請求項4】 前記ブロッキング剤が、抗APRILレセプター抗体である、請求項3に記載の使用。
【請求項5】 前記ブロッキング剤が、少なくとも1つの化学療法剤と組み合わせて患者に投与される、請求項1に記載の使用。
【請求項6】 前記患者に放射線治療を施す工程をさらに包含する、請求項4に記載の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5878697P | 1997-09-12 | 1997-09-12 | |
US60/058,786 | 1997-09-12 | ||
US7938498P | 1998-03-26 | 1998-03-26 | |
US60/079,384 | 1998-03-26 | ||
PCT/US1998/019191 WO1999012965A2 (en) | 1997-09-12 | 1998-09-11 | April- a novel protein with growth effects |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001515712A JP2001515712A (ja) | 2001-09-25 |
JP2001515712A5 true JP2001515712A5 (ja) | 2006-01-05 |
Family
ID=26738027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000510770A Pending JP2001515712A (ja) | 1997-09-12 | 1998-09-11 | 増殖効果を有する新規タンパク質−april |
Country Status (20)
Country | Link |
---|---|
US (3) | US20030138884A1 (ja) |
EP (1) | EP1027431A2 (ja) |
JP (1) | JP2001515712A (ja) |
KR (1) | KR100618492B1 (ja) |
CN (1) | CN1195849C (ja) |
AU (1) | AU759717B2 (ja) |
BR (1) | BR9812634A (ja) |
CA (1) | CA2303615A1 (ja) |
CZ (1) | CZ294615B6 (ja) |
EA (1) | EA005411B1 (ja) |
EE (1) | EE200000147A (ja) |
HU (1) | HUP0004611A3 (ja) |
IL (1) | IL134537A0 (ja) |
IS (1) | IS5378A (ja) |
NO (1) | NO20001242L (ja) |
NZ (1) | NZ503850A (ja) |
PL (1) | PL339463A1 (ja) |
SK (1) | SK3542000A3 (ja) |
TR (1) | TR200000669T2 (ja) |
WO (1) | WO1999012965A2 (ja) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541224B2 (en) | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
US7217788B2 (en) | 1996-03-14 | 2007-05-15 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta polypeptides |
AU1700999A (en) * | 1997-11-26 | 1999-06-15 | Eli Lilly And Company | Tnf ligand family gene |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
EP2319527A3 (en) | 1999-01-25 | 2011-10-12 | Biogen Idec MA Inc. | BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
DK1210425T4 (en) | 1999-08-17 | 2015-08-10 | Apotech R & D Sa | BAFF receptor (BCMA), an immunoregulatory agent |
UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
WO2001025256A2 (en) * | 1999-10-06 | 2001-04-12 | University Of Utah Research Foundation | Trdl-1-gamma, a novel tumor necrosis-like ligand |
CA2399387C (en) | 2000-02-11 | 2015-11-03 | Biogen, Inc. | Heterologous polypeptide of the tnf family |
AU2006201471B2 (en) * | 2000-02-16 | 2009-07-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of TNF-related molecules |
EP1255558B1 (en) * | 2000-02-16 | 2006-06-14 | Genentech, Inc. | Anti-april antibodies and hybridoma cells |
AU2001261557B2 (en) * | 2000-05-12 | 2005-06-30 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
AU2001282856A1 (en) * | 2000-06-15 | 2001-12-24 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
GB2370273A (en) * | 2000-12-20 | 2002-06-26 | Viaxxel Biotech Gmbh | Compounds that affect CD83 expression |
BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
JP2004537290A (ja) | 2001-05-24 | 2004-12-16 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 腫瘍壊死因子δ(APRIL)に対する抗体 |
US7381792B2 (en) | 2002-01-04 | 2008-06-03 | Xencor, Inc. | Variants of RANKL protein |
WO2003057856A2 (en) | 2002-01-04 | 2003-07-17 | Xencor | Dominant negative proteins and methods thereof |
US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
WO2004089982A2 (en) * | 2003-01-06 | 2004-10-21 | Xencor | April variants and methods thereof |
JP5524441B2 (ja) | 2003-03-28 | 2014-06-18 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 短縮されたbaffレセプター |
WO2005075511A1 (en) * | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
WO2005113598A2 (en) * | 2004-05-21 | 2005-12-01 | Xencor, Inc. | Tnf super family members with altered immunogenicity |
US7947805B2 (en) | 2004-12-23 | 2011-05-24 | Merck Serono S.A. | BCMA polypeptides and uses thereof |
JP5118037B2 (ja) | 2005-08-09 | 2013-01-16 | ザイモジェネティクス, インコーポレイテッド | Taci融合分子を用いた異常細胞増殖の処置及び予防のための方法 |
AU2006278229B2 (en) | 2005-08-09 | 2011-10-27 | Ares Trading S.A. | Methods for treating B-cell malignancies using TACI-Ig fusion molecule |
EP1934258B1 (en) * | 2005-09-26 | 2011-03-02 | Enzo Life Sciences (ELS) AG | Antibodies against april as biomarkers for early prognosis of lymphoma patients |
EP3037544A1 (en) | 2005-10-13 | 2016-06-29 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases |
AU2006318539B2 (en) | 2005-11-23 | 2012-09-13 | Genentech, Inc. | Methods and compositions related to B cell assays |
AU2007249223B2 (en) | 2006-05-15 | 2012-08-02 | Ares Trading S.A. | Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
SI2403528T1 (sl) | 2009-03-02 | 2016-07-29 | Aduro Biotech Holdings, Europe B.V. | Protitelesa proti proliferacijo inducirajočemu ligandu (april) |
EP2542679A1 (en) * | 2010-03-05 | 2013-01-09 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | B-cell stimulating fusion proteins of an antigen with baff or april |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
NL2011406C2 (en) * | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
IL297607B2 (en) * | 2013-09-23 | 2024-01-01 | Regeneron Pharma | Non-human animals with a humanized gene for SIGNAL-REGULATORY PROTEIN |
GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
RU2671101C1 (ru) * | 2013-11-19 | 2018-10-29 | Регенерон Фармасьютикалс, Инк. | Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда |
NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
EP3380522B1 (en) | 2015-11-25 | 2023-11-08 | Visterra, Inc. | Antibody molecules to april and uses thereof |
US11484027B2 (en) | 2020-10-29 | 2022-11-01 | Industrial Polymers and Chemicals, Inc. | Air filter with pathogen monitoring and inactivation |
AU2022327178A1 (en) | 2021-08-11 | 2024-03-28 | Akso Biopharmaceutical, Inc. | METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5176996A (en) * | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5256775A (en) * | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5264564A (en) * | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
AU6166396A (en) * | 1995-06-07 | 1996-12-30 | Biogen, Inc. | Complexes of modified lymphotoxins as pharmaceutical prepara tions |
AU726486C (en) * | 1996-03-14 | 2004-02-05 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
US6509170B1 (en) * | 1996-03-14 | 2003-01-21 | Human Genome Sciences, Inc. | Polynucleotides encoding human tumor necrosis factor delta |
US6171787B1 (en) * | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
-
1998
- 1998-09-11 EP EP98946066A patent/EP1027431A2/en not_active Withdrawn
- 1998-09-11 AU AU93162/98A patent/AU759717B2/en not_active Ceased
- 1998-09-11 SK SK354-2000A patent/SK3542000A3/sk unknown
- 1998-09-11 IL IL13453798A patent/IL134537A0/xx unknown
- 1998-09-11 KR KR1020007002577A patent/KR100618492B1/ko not_active IP Right Cessation
- 1998-09-11 JP JP2000510770A patent/JP2001515712A/ja active Pending
- 1998-09-11 CN CNB988090384A patent/CN1195849C/zh not_active Expired - Fee Related
- 1998-09-11 TR TR2000/00669T patent/TR200000669T2/xx unknown
- 1998-09-11 EA EA200000310A patent/EA005411B1/ru unknown
- 1998-09-11 CZ CZ2000869A patent/CZ294615B6/cs not_active IP Right Cessation
- 1998-09-11 WO PCT/US1998/019191 patent/WO1999012965A2/en not_active Application Discontinuation
- 1998-09-11 NZ NZ503850A patent/NZ503850A/xx unknown
- 1998-09-11 PL PL98339463A patent/PL339463A1/xx unknown
- 1998-09-11 EE EEP200000147A patent/EE200000147A/xx unknown
- 1998-09-11 BR BR9812634-2A patent/BR9812634A/pt not_active Application Discontinuation
- 1998-09-11 HU HU0004611A patent/HUP0004611A3/hu unknown
- 1998-09-11 CA CA002303615A patent/CA2303615A1/en not_active Abandoned
-
2000
- 2000-02-18 IS IS5378A patent/IS5378A/is unknown
- 2000-03-09 NO NO20001242A patent/NO20001242L/no unknown
-
2002
- 2002-05-01 US US10/138,073 patent/US20030138884A1/en not_active Abandoned
-
2004
- 2004-02-12 US US10/778,890 patent/US20050112596A1/en not_active Abandoned
-
2005
- 2005-12-06 US US11/296,049 patent/US20060084148A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001515712A5 (ja) | ||
IL195723A (en) | Use of p53 inhibitors for the preparation of medicament | |
HK1084862A1 (en) | Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject | |
WO2004062604A3 (en) | Treatment of cancer with 2-deoxyglucose | |
TR200001891T2 (tr) | ASPB28- İnsan ensülini ve kullanımı. | |
PL287844A1 (en) | Method of obtaining an oraly administered composite medicine for treating interstinal inflamatory diseases | |
RU2002127804A (ru) | Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения | |
CA2334267A1 (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c | |
CA2214503A1 (en) | Method for treating tumors | |
AR016798A1 (es) | Uso de una cepa de lactobacillus para la elaboracion de un medicamento | |
JP2004537500A5 (ja) | ||
WO2000040229A3 (en) | Synergistic tumorcidal response induced by histamine | |
CA2032475A1 (en) | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines | |
EP1304108A3 (en) | Anti-arrhythmic composition and methods of treatment | |
MY105798A (en) | Treatment of leukocyte dysfunction with gm-csf. | |
JP2002530353A5 (ja) | ||
AU3401093A (en) | Therapeutic agent for threatened abortion | |
Corazziari | Need of the ideal drug for the treatment of chronic constipation | |
EP0795332A3 (en) | Medical use of gamma-interferon in interstitial lung diseases | |
TWI263502B (en) | Pharmaceutical preparation for treating ischemic disease of heart or limbs | |
EA199800770A1 (ru) | Лекарственный препарат для терапевтического лечения вирусного гепатита | |
WO2001045642A3 (en) | Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease | |
FR2786699B1 (fr) | Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles | |
CN1053577C (zh) | 烧烫散 | |
James | Ribavirin approved for hepatitis C combination treatment |